Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

齐平 - NMPA Drug Approval Details

Approvals/NMPA/Levocetirizine Dihydrochloride Tablets

Approved

化学药品

Levocetirizine Dihydrochloride Tablets

江苏恒瑞医药股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Feb 19, 2021
Approval ID: 7Leaf76584A
Company: 江苏恒瑞医药股份有限公司
Type: 化学药品

Approval Details

Approval Id: 7Leaf76584A
Approval Number: 国药准字H20060132
Generic Name: 盐酸左西替利嗪片
Generic Name En: Levocetirizine Dihydrochloride Tablets
Trade Name: 齐平
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 5mg
Reg Date: 2021-02-19
Company Name: 江苏恒瑞医药股份有限公司
Company Address: 连云港经济技术开发区黄河路38号
Production Company Name: 江苏恒瑞医药股份有限公司
Production Company Address: 连云港经济技术开发区黄河路38号
Company Detail Path: /organization/hengrui-pharma
Production Company Detail Path: /organization/hengrui-pharma

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Feb 19, 2021

Approval ID

7Leaf76584A

Type

化学药品

Back to NMPA Approvals